These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 1618602)

  • 1. The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor.
    Bell RL; Young PR; Albert D; Lanni C; Summers JB; Brooks DW; Rubin P; Carter GW
    Int J Immunopharmacol; 1992 Apr; 14(3):505-10. PubMed ID: 1618602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Hydroxycinnamic Acid Esters as Novel 5-Lipoxygenase Inhibitors That Affect Leukotriene Biosynthesis.
    Boudreau LH; Lassalle-Claux G; Cormier M; Blanchard S; Doucet MS; Surette ME; Touaibia M
    Mediators Inflamm; 2017; 2017():6904634. PubMed ID: 28680195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase.
    Rubin P; Dubé L; Braeckman R; Swanson L; Hansen R; Albert D; Carter G
    Agents Actions Suppl; 1991; 35():103-16. PubMed ID: 1781415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis.
    Malo PE; Bell RL; Shaughnessy TK; Summers JB; Brooks DW; Carter GW
    Pulm Pharmacol; 1994 Apr; 7(2):73-9. PubMed ID: 8081074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A-78773: a selective, potent 5-lipoxygenase inhibitor.
    Bell RL; Brooks DW; Young PR; Lanni C; Stewart AO; Bouska J; Malo PE; Carter GW
    J Lipid Mediat; 1993; 6(1-3):259-64. PubMed ID: 8395248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group.
    Liu MC; Dubé LM; Lancaster J
    J Allergy Clin Immunol; 1996 Nov; 98(5 Pt 1):859-71. PubMed ID: 8939149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude.
    Grissom CK; Richer LD; Elstad MR
    Chest; 2005 Feb; 127(2):565-70. PubMed ID: 15705997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
    Zweifel BS; Hardy MM; Anderson GD; Dufield DR; Pufahl RA; Masferrer JL
    Eur J Pharmacol; 2008 Apr; 584(1):166-74. PubMed ID: 18295198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High ability of zileuton ((±)-1-(1-benzo[b]thien-2-ylethyl)-1-hydroxyurea) to stimulate I
    Hung TY; Huang CW; Wu SN
    Eur J Pharmacol; 2020 Nov; 887():173482. PubMed ID: 32795513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of leukotrienes in inflammation and leukotriene inhibitors].
    Kupczyk M; Kuna P
    Pol Merkur Lekarski; 1999 Sep; 7(39):85-93. PubMed ID: 10598480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multitarget drugs: synthesis and preliminary pharmacological characterization of zileuton analogues endowed with Dual 5-LO inhibitor and NO-dependent activities.
    Boschi D; Giorgis M; Cena C; Talniya NC; Di Stilo A; Morini G; Coruzzi G; Guaita E; Fruttero R; Gasco A
    ChemMedChem; 2010 Sep; 5(9):1444-9. PubMed ID: 20645382
    [No Abstract]   [Full Text] [Related]  

  • 12. [5-lipoxygenase inhibitors in asthma therapy].
    Tanaka R
    Nihon Rinsho; 1996 Nov; 54(11):3040-4. PubMed ID: 8950951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9.
    Tu XK; Yang WZ; Shi SS; Chen CM; Wang CH
    Neurol Res; 2009 Oct; 31(8):848-52. PubMed ID: 19309543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor.
    Meltzer SS; Hasday JD; Cohn J; Bleecker ER
    Am J Respir Crit Care Med; 1996 Mar; 153(3):931-5. PubMed ID: 8630575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asthma therapy with agents preventing leukotriene synthesis or action.
    Drazen JM
    Proc Assoc Am Physicians; 1999; 111(6):547-59. PubMed ID: 10591083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Zileuton-Hydroxycinnamic Acid Hybrids: Synthesis and Structure-Activity Relationship towards 5-Lipoxygenase Inhibition.
    Chiasson AI; Robichaud S; Ndongou Moutombi FJ; Hébert MPA; Mbarik M; Surette ME; Touaibia M
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33066378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease.
    Berger W; De Chandt MT; Cairns CB
    Int J Clin Pract; 2007 Apr; 61(4):663-76. PubMed ID: 17394438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and clinical activity of zileuton and A-78773.
    Bell RL; Lanni C; Malo PE; Brooks DW; Stewart AO; Hansen R; Rubin P; Carter GW
    Ann N Y Acad Sci; 1993 Nov; 696():205-15. PubMed ID: 8109828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-lipoxygenase inhibitory activity of zileuton.
    Carter GW; Young PR; Albert DH; Bouska J; Dyer R; Bell RL; Summers JB; Brooks DW
    J Pharmacol Exp Ther; 1991 Mar; 256(3):929-37. PubMed ID: 1848634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing therapeutically effective 5-lipoxygenase inhibitors.
    McMillan RM; Walker ER
    Trends Pharmacol Sci; 1992 Aug; 13(8):323-30. PubMed ID: 1413091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.